PMID: 11320043Apr 26, 2001Paper

A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia

Archives of Disease in Childhood. Fetal and Neonatal Edition
A R Bedford RussellE G Davies

Abstract

The primary objective was to investigate the safety of recombinant human granulocyte colony stimulating factor (rhG-CSF) for the treatment of very low birthweight infants (VLBW) with sepsis and relative neutropenia, specifically with regard to worsening of respiratory distress and thrombocytopenia and all cause mortality. Secondary objectives were to evaluate duration of ventilation, intensive care, and antibiotic use as markers of efficacy. Neonates (< or = 28 days) in intensive care, with birth weights of 500-1500 g, absolute neutrophil count (ANC) of < or = 5 x 10(9)/l, and clinical evidence of sepsis, were randomly assigned to receive either rhG-CSF (10 microg/kg/day) administered intravenously (n = 13), or placebo (n = 15) for a maximum of 14 days, in addition to standard treatment and antibiotics. All adverse events, oxygenation index, incidence of thrombocytopenia, all cause mortality, duration of ventilation, intensive care and antibiotic treatment, and ANC recovery were compared between the two groups. Adverse events and oxygenation index were not increased by, and thrombocytopenia was not attributable to, treatment with rhG-CSF. At 6 and 12 months postmenstrual age, there were significantly fewer deaths in the group r...Continue Reading

References

Jun 11, 1976·The Journal of Pediatrics·J J HutterE R Wayne
Oct 1, 1972·Archives of Disease in Childhood·J Gregory, E Hey
Feb 1, 1980·The Journal of Pediatrics·R D Christensen, G Rothstein
Jan 22, 1982·JAMA : the Journal of the American Medical Association·A G Philip
Jan 1, 1982·Biology of the Neonate·S H ErdmanG Rothstein
Jan 1, 1995·Archives of Disease in Childhood. Fetal and Neonatal Edition·A R RussellE Gordon-Smith
Oct 1, 1994·The Journal of Pediatrics·R L SchelonkaJ Butler
May 1, 1993·The Pediatric Infectious Disease Journal·R L RodwellP H Gray
Jul 1, 1993·Archives of Disease in Childhood·S ArnonM Silverman
May 8, 1998·The New England Journal of Medicine·S B Levy

❮ Previous
Next ❯

Citations

Mar 7, 2002·Current Opinion in Pediatrics·Hilton M BernsteinRobert D Christensen
Mar 18, 2003·Current Opinion in Pediatrics·Mandhir SuriMitchell S Cairo
Nov 16, 2004·Critical Care Medicine·Juan C Gea-BanaclocheCatherine Cordonnier
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Joseph A Carcillo
Dec 11, 2013·Current Opinion in Hematology·Akhil Maheshwari
Feb 24, 2004·Archives of Disease in Childhood. Fetal and Neonatal Edition·N A Murray, I A G Roberts
Feb 7, 2004·Pediatric Research·Jason A GerstingDarlene A Calhoun
Nov 15, 2002·Pediatric Clinics of North America·Wade Kyono, Thomas D Coates
Mar 7, 2006·Neonatal Network : NN·Susan Givens Bell
Aug 15, 2003·The Cochrane Database of Systematic Reviews·R CarrC Doré
Mar 24, 2004·Acta Paediatrica. Supplement·R Carr, N Modi
Mar 5, 2020·Revista da Associação Médica Brasileira·Antonio SilvinatoGabriel Nogueira Bastos Soledade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.